Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 243.70K | 251.10K | 3.96M | 3.56M | 163.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 243.70K | 251.10K | 3.96M | 3.56M | 163.60K |
| Cost of Revenue | 5.03M | 4.10M | 4.94M | 2.92M | 3.66M |
| Gross Profit | -4.79M | -3.85M | -980.50K | 647.40K | -3.50M |
| SG&A Expenses | 2.26M | 3.78M | 3.27M | 2.56M | 2.91M |
| Depreciation & Amortization | 2.80K | 2.80K | 6.80K | 6.80K | 6.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.29M | 7.88M | 8.22M | 5.48M | 6.58M |
| Operating Income | -7.05M | -7.63M | -4.26M | -1.92M | -6.41M |
| Income Before Tax | -6.64M | -7.21M | -5.71M | -2.12M | -6.10M |
| Income Tax Expenses | -- | -- | 3.10K | -- | -- |
| Earnings from Continuing Operations | -6.64M | -7.21M | -5.71M | -2.12M | -6.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.64M | -7.21M | -5.71M | -2.12M | -6.10M |
| EBIT | -7.05M | -7.63M | -4.26M | -1.92M | -6.41M |
| EBITDA | -7.04M | -7.63M | -4.25M | -1.91M | -6.41M |
| EPS Basic | -0.28 | -0.32 | -0.34 | -0.13 | -0.36 |
| Normalized Basic EPS | -0.18 | -0.20 | -0.15 | -0.06 | -0.23 |
| EPS Diluted | -0.28 | -0.32 | -0.34 | -0.13 | -0.36 |
| Normalized Diluted EPS | -0.18 | -0.20 | -0.15 | -0.06 | -0.23 |
| Average Basic Shares Outstanding | 23.46M | 22.64M | 16.74M | 16.73M | 16.73M |
| Average Diluted Shares Outstanding | 23.46M | 22.64M | 16.74M | 16.73M | 16.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |